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ABSTRACT
Recent literature concerning the use of polymer and ceramic coatings for a variety of biomedical
applications is surveyed in this review. Applications have been grouped into six broad categories:
orthopaedic materials, cardiovascular stents, antibacterial surfaces, drug delivery, tissue
engineering and biosensors. Polymer and ceramic coatings add enhanced corrosion protection,
antiwear, antibacterial and biocompatibility properties to various substrates for biomedical
applications. Processes favoured for polymer coating formation included dip, electrodeposition,
spin (including electrospin) and spray (including electrospray and ultrasonic spray). Ceramic
coatings were formed using magnetron sputtering and a combination of 3-D printing and in-situ
mineralisation, among others. The review period is from 2017 to the present (mid-2021).
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Introduction
Polymer and ceramic coatings for biomedical applications are
areas of increasing interest.1 Such coatings render their
underlying substrate materials with biocompatibility,
increased mechanical strength, wear resistance, corrosion
resistance and functionality. The aim of this review is to
bring up-to-date a previous review on the subject published
in 2014.2 In this paper, however, ceramic coatings in addition
to polymer coatings are included. Ceramic coatings,
especially in the biomedical area, are gaining ever increasing
popularity.3 Hydroxyapatite (HAP, Ca10(PO4)6(OH)2) is the
obvious choice of ceramic material, due its similar compo-
sition to bone and biocompatibility, although it does have
poor mechanical stability forbidding load-bearing use;4 there-
fore, attempts have been made to improve this.
As in the 2014 review,2 publications have been grouped
into six main categories: orthopaedic materials,4–18 cardiovas-
cular stents,19–41 antibacterial surfaces,42–56 drug delivery,57–
73 tissue engineering,74–87 and biosensors.88–95 Each area is
broadly structured from coatings on metallic to non-metallic
surfaces. Papers featured in this review have been selected
without application bias or emphasis from a larger pool of rel-
evant studies to provide a spread of developments in the field
to encourage the reader to want to explore further. The
review period dates from 2017 to mid-2021.
Applications
Orthopaedic materials
Bacterial infection resulting from orthopaedic implants (osteo-
myelitis) is a leading cause of implant failure and revision
surgery.5 Chitosan (CS, a natural polysaccharide derived from
crustaceans) combined with Aloe vera (CS/AV) loaded with
gentamicin sulphate (GS) has been electrodeposited under
potentiostatic conditions (–2.5 V vs. SCE, 3-electrode system
for 45 min) onto a Ti alloy. Increased antibacterial activity
against Staphylococcus aureus (S. aureus) and Escherichia coli
(E. coli)was found.5 Chitosan-bioactive glass (CS-BG) nanocom-
posite coatings have been applied to Ti6Al4V using cathodic
electrophoretic deposition by Mahlooji et al.6 Increased BG
content enhanced the apatite-forming ability of the coating,
adhesion strength, roughness and wettability; good cell
attachment and no significant levels of cytotoxicity were
reported following this procedure. Mohan Raj et al. anodised
Ti (at 50 V DC for 120 min in an electrolyte containing 3%
sodium fluorosilicate), producing a TiO2-SiO2 surface onto
which was subsequently electrodeposited (−2.5 V vs. SCE for
45 min) a CS-lysine biopolymer coating and a final electrode-
posited (−2.5 V vs. SCE for 45 min) coating GS (50 mg mL−1
GS in the electrolyte), as a model drug.7 The coating offered
improved corrosion resistance and antimicrobial activity
(S. aureus and E. coli) in addition to good osteoblast adhesion
and growth. Kumari et al. carried out a systematic review on
the use of CS-modified metallic and polymer scaffolds that
are reported to enhance the biocompatibility, corrosion resist-
ance and antibacterial properties of metallic implants.8 Coating
methods for CS using electrophoretic deposition, sol–gel
methods, dip coating, spin coating or electrospinning are
discussed.
Although Ti is used widely for implants owing to its excel-
lent biocompatibility, the metal does suffer from insufficient
osteointegration that can affect implant longevity. Poly(N-
methylpyrrole) (PNP) was electropolymerised on Ti using
cyclic voltammetry (0.2 M N-methylpyrrole in 0.5 M sodium
salicylate, 0.5–2.0 V vs. SCE, 10 cycles, 100 mV s−1) followed
by an electrodeposited layer of La-HAP (galvanostatic
mode, 9 mA cm−2, 30 min).4 This coating system led to
decreased bacterial (S. aureus and E. coli) colonisation and
increased microhardness, suggesting reduced likelihood for
implant failure.4 Introducing the rare metal lanthanum
(La3+) into the HAP lattice increases the mechanical proper-
ties of HAP,9 and acts as an antibacterial agent. The conduct-
ing polymer PNP, also has the potential for reducing
inflammation and infection, and giving increased hardness
and colonisation of the coating, compared to La-HAP alone.
Krishnakumar and Senthilvelan have reviewed the use of
polymer composites in orthopaedic and dental applications
over the past 10 years.10 The review focused on polymers,
some of which detail HAP/polymer composites replacing
metals as bulk materials, however, rather than coatings per se.
Pan et al. examined zinc, cerium and selenium substituted
HAP / poly (sorbitol sebacate glutamate) (PSSG) composite
coatings on Ti (prepared by applying 50 V for 15 min at 27°
C to Ti in 10 w/w% PSSG in HAP solution);11 the metal ion sub-
stitution and the addition of PSSG were both found to
increase microhardness. The composite coatings (containing
Zn2+, Ce2+ and SeO3
2-) showed increased cell attachment, pro-
liferation and differentiation to human osteoblasts MG-63
cells compared to similar composite coatings without these
ions or with only single ion inclusion. Abdal-hay et al.
coated Ti with a composite layer of magnesium particles
and biodegradable polyurethane (PU) using spin-coating
(Figure 1).12 Superior corrosion resistance was found,
although an alkaline-treatment step of the Ti prior to
coating was important for enhanced adhesion. Cellular
adhesion and proliferation was observed. The conducting
polymer polypyrrole (PPy) has been electrodeposited, as a
pectin/PPy composite loaded with gentamicin (GM), onto
TiNbZr alloy.13 Sustained release of GM was observed from
the composite, and coatings with 10 wt% GM showed the
lowest corrosion rate and highest biocompatibility and anti-
bacterial performance.
Shokri et al. examined the pre-treatment and deposition of
highly crystalline nano-HAp on to NiTi using the sol–gel spin
coating technique.14 A significant decrease in corrosion and
Ni2+ release was found, and the materials showed enhanced
biocompatibility.
Mendolia et al. coated AISI304 steel with brushite-hydro-
xyapatite/polyvinyl acetate using galvanic deposition (2 com-
partment cell; catholyte: 0.061 M Ca(NO3)2⋅4H2O, 0.036 M
NH4H2PO4 and varying concentrations of vinyl acetate;
anolyte: 1 M NaCl), different temperatures (25 and 50°C),
deposition times (24 and 72 h) and different sacrificial
anodes (zinc and aluminium, standard potentials of −0.762
and −1.66 V, respectively).15 The best coatings were obtained
using Al anodes. Cell viability assays showed that the coating
enabled the stainless steel to support biocompatibility
(MC3T3-E1 osteoblastic cells).
Samiee et al. formed a thin TiO2 layer and also a TiO2/MgO
double layer on AZ91D alloy (a magnesium die-cast alloy with
excellent mechanical properties and corrosion resistance)
using magnetic sputtering.16 TiO2 and MgO phases were
the main phases in the coatings (XRD examination), although
in the double-layer coating, MgTiO3 and Mg2TiO4 were
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additionally formed at the coating/substrate interface (Figure
2). The double layer coating showed the best corrosion resist-
ance and enhanced biocompatibility and bio-adhesion was
reported.
A dip-coating of polydopamine (PDA) containing chlor-
hexidine (CHX) applied to stainless steel was shown to
prevent Staphylococci colonisation.17 If the metal was
dipped in PDA without CHX and then treated with CHX,
however, this approach was found to compromise cell
growth compared to the single dip method alone. PDA con-
tinues to be used as a coating for many types of surfaces; its
use for orthopaedic implants has been reviewed by Jia et al.18
The authors comment that PDA coatings provide a useful,
cost-effective method for bestowing osteogenic properties
and for subsequent modification using hydroxyapatite. Anti-
bacterial properties can also be included by the addition of
silver particles or other antimicrobial compounds (added
during the process) to PDA coatings. The authors also state
that a more detailed understanding of the interactions
between cells and between PDA and extracellular matrix
should be studied.
Cardiovascular stents
Cardiovascular disease (CVD) claims 17.9 million lives every
year, representing 31% of deaths globally.19 Cardiovascular
stents provide a treatment option from narrowed or
blocked arteries, with the majority of stents being made of
either 316L stainless steel or cobalt-chromium (Co-Cr) due
to their excellent mechanical properties and corrosion resist-
ance.20 Restenosis and thrombosis, however, can cause com-
plications20 and various coatings continue to be investigated.
Borhani et al.,21 Beshchasna et al.,22 Livingston and Tan,23
and Lee and de la Torre Hernandez24 have reviewed the inno-
vative new advancements in the design and fabrication of
cardiovascular stents. Borhani et al. have given particular
focus on cardiovascular drug-eluting stents (DES), reviewing
their design and development, as well as potential improve-
ments of existing stents and a review on the fabrication of
novel stent prototypes.21 Beshchasna et al. also emphasise
the mechanical aspects of stents and provide information
on recently filed patents within the field.22 Livingston and
Tan23 consider recent DES coating techniques and drug
release profiles, while Lee and de la Torre Hernandez24
provide suggestions regarding the optimal characteristics of
future coronary stents.
Torii et al. reviewed stent designs, and their preclinical and
pathology studies, focussing on neointimal coverage, throm-
boresistance and completeness of healing, concluding that
further research is required to establish the relationship
between modifications in stent design and improved
outcomes.25
Rykowska et al. reviewed the design, materials and tech-
nologies used in the preparation of DES as well as drug-
eluting balloons (DEBs).26 With particular detail provided
Figure 1. Spin-coating of Ti with PU showing electrostatic intermolecular interaction between the Ti and the polymer chain. Used with permission.6
Figure 2. Cross-section showing composition of bilayer TiO2 and TiO2/MgO coatings on AZ91D magnesium alloy for orthopaedic applications. Used with
permission.16
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into the most commonly used and researched polymers, this
review concludes that although further research is required to
achieve comparable efficacy and safety data, DES and DEBs
present as significant alternatives for use in cardiac surgery.
Considering the current drawbacks thought to contribute
to DES failure, Nojic et al.27 have reviewed the clinical evi-
dence supporting the use of biodegradable polymer and
polymer free DES stents; Qiu and Zhao28 reviewed the early
stage development of bioresorbable stents (BRSs), taking
into account both experimental and modelling work.
Krackhardt et al. conducted an unselected, single-armed,
multicentre ‘all corners’ observational study enrolling partici-
pants from both Europe and Asia.29 The clinical trial investi-
gated the safety and efficacy of a polymer-free sirolimus
(SRL, an immunosuppressant) coated, ultrathin strut DES con-
centrating on acute coronary syndrome. The study also con-
sidered stable coronary artery disease (CAD) with dual
antiplatelet therapy (DAPT) over short, (≤ 6 months) vs.
long (> 6 months) time periods. The authors concluded PF-
SES angioplasty to be safe and effective and that DAPT dur-
ation of over 6 months did not have lower target lesion revas-
cularisation rates in comparison to those with durations of up
to 6 months, indicating that in patients with stable CAD,
extended DAPT duration past 6 months did not improve clini-
cal outcomes.
Noting the potential of stents that can inhibit restenosis
without adversely affecting re-endothelialisation, McKittrick
et al. optimised an electrospray deposition process, produ-
cing a series of rapid release accelerate™ AT-sirolimus coat-
ings offering similar release kinetics, drug load and coating
thickness to DES used clinically.30 The coatings also demon-
strated bioactive properties, by stimulating attachment of
primary porcine endothelial cells.
Jeger et al. identified that clinical outcome data related to
the use of DEBs (also known as drug-coated balloons, DCBs)
beyond one year is needed. They also conducted a long-
term follow-up of a multicentre, randomised, open-label,
non-inferiority trial (2012–2017).31 The study examined pacli-
taxel-coated DCBs, and everolimus- and paclitaxel-eluting
DES. The trial results indicated that in the use of DCBs
(vs.DES) in the treatment of de novo coronary artery small
vessel disease, efficacy and safety were maintained for up
to 3 years.
Bakola et al. fabricated a drug delivery nano-system con-
sisting of electrospun hydrophobic polylactic acid (PLA)
fibrous scaffold loaded with dipyridamole (a nucleoside trans-
port inhibitor and a phosphodiesterase enzyme-3 (PDE3)
inhibitor), added during the electrospinning process.32 The
surface morphology and topography were found to be suit-
able for tissue engineering, and further studies revealed
that the fibrous nanoplatforms enhance cytocompatibility
when used with mice fibroblasts (L929) and are capable of
sustaining a controlled release of dipyridamole.
Bae et al. fabricated a peptide-coated stent WKYMVm (Trp-
Lys-Tyr-Met-Val-D-Met) utilising a peptide specifically syn-
thesised to stimulate endothelial cell proliferation;33 this
was achieved by essentially dip-coating a Co-Cr bare metal
stent (BMS) in dopamine followed by a solution containing
peptides. Results from mechanical testing, endothelial cell
proliferation and pre-clinical animal studies demonstrated
that the peptide-coated stent was not inferior to the drug-
eluting scaffolds tested for comparison. The authors also
suggest a secondary coating with immunosuppressive
drugs, such as everolimus and biolimus, could also be
incorporated.
Utilising an ultrasonic spray technique, Roopmani et al.
coated a bare metal stent with a drug loaded (atorvastatin
and fenofibrate) biodegradable polyester poly(L-lactide-co-
caprolactone) (PLCL) coating.34 The coating was found to
be uniform, defect free and biocompatible (Wistar rat
study), anti-inflammatory and antithrombotic properties
were also exhibited.
Navarro et al. investigated the reasons behind the clinical
failure of gold and carbon-coated 316L stainless steel stents
(Inflow Gold Flex System, Inflow Dynamics, and Carbon
filmTM Coated Coronary Stent, Sorin, Biomedical, respect-
ively); many of these systems were approved and put into
service globally, although had to be withdrawn due to high
levels of failures, with little understanding of the mechan-
ism.20 The Au and C coatings were found to result in pitting
corrosion of the underlying 316L substrate, leading to a
release of toxic ions. In addition, the high restenosis rate of
Au coated 316L stents was attributed to a synergistic effect
of Au ions with the ions from the pitting corrosion event.
The authors propose complementary techniques that can
be used alongside the FDA guidance during early non-clinical
engineering tests.
Realising the need for improved degradability in biocom-
patible phosphorylcholine based polymer coatings, Liu et al.
presented a method to synthesise a biodegradable phos-
phorylcholine copolymer utilised to form a stable coating,
on hydrophobicly silanised glass, via ultrasonic spraying.35
The synthesised copolymer coatings exhibited biocompatibil-
ity, anti-adhesion properties and a sustained release profile of
rapamycin (also known as SRL).
To address the current problems associated with in-stent
stenosis, Yang et al. presented a step-wise method utilising
a metal (copper)-catechol-(amine) (MCA) strategy; Cu2+, cate-
chol and a diamine form a complex on the surface of a 316L
stainless steel when dipped into the solution.36 This surface
was then coated with heparin (carbodiimide chemistry) and
a nitric oxide (NO)-releasing coating to produce a multifunc-
tional endothelium-mimicking surface, that controllably
released these compounds.36 Li et al. also recognised the
benefits of NO (a signalling molecule in vascular biology) in
CVD and developed an NO-generating coating (Cu2+-Dopa)
(dip-coating, 24 h) utilising a metal-catecholamine frame-
work, which promoted re-endothelisation, suppressed throm-
bosis and showed a reduction in intimal hyperplasia
(accumulation of cells) in vivo.37
In an effort to enhance the corrosion resistance of biore-
sorbable magnesium alloy (WE43) stents, Lakalayeh et al.
investigated the use of FDA approved polymers, PLA, polyca-
prolactone (PCL) and poly(lactic-co-glycolic acid) (PLGA)
applied as dip-coatings.38 Both PLA and PLGA exhibited cor-
rosion resistance, with PLA also demonstrating
biocompatibility.
Also, noting the need for enhanced corrosion resistance,
Xu et al. dip-coated Mg alloy (AZ31) stents with silk fibroin,
followed by an ultrasonic spray coating of PDLLA and PCL
containing SRL;39 release of SRL was demonstrated, with
ethanol treatment of the coated stent shown to slow the
release of the drug. Biocompatibility was established utilising
human umbilical vein endothelial cells and minimal platelet
adhesion; the coated stent also exhibited uniform corrosion,
a property thought to be advantageous in maintaining the
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stent’s radial strength. The same authors also performed an
earlier similar study, using similar polymers without the silk
fibroin addition.40
To increase the growth of endothelial cells on Mg–Zn–Y–
Nd alloy surface and promote the wider use of magnesium
alloys, Chen et al. immobilised (6 h immersion) a specific
link peptide of endothelial cells, Arg-Glu-Asp-Val (REDV),
onto a PDA-deposited (24 h immersion) Mg–Zn–Y–Nd alloy
surface.41 The obtained coating exhibited anti-hyperplasia
and anti-inflammatory properties.
Antimicrobial surfaces
Huang and Ghasemi have reviewed mechanically and chemi-
cally robust anti-biofouling hydrophilic polymer coatings;42
these were classified into six types: (i) 3D-grafted coatings,
(ii) hierarchical spheres-based coatings, (iii) inorganic nano-
materials-reinforced coatings, (iv) hydrolysis-based coating,
(v) semi-interpenetrating structure-based coatings, and (vi)
layer-by-layer (LbL) assembled coatings (Figure 3).
The antibacterial coating polyterphenol has been plasma
polymerised on four types of Ti surfaces, each with different
micro- and nano-scale topographies;43 the antimicrobial
(E. coli and Pseudomonas aeruginosa) action was significantly
enhanced with polymers plasma-coated on Ti with lower
degrees of nanoscale roughness, i.e. after mechanical and
chemical polishing. Valliammai et al. produced polymer coat-
ings containing citral and thymol as active ingredients on Ti
using spin coating;44 sustained release was noted for 60
days and the coating effectively inhibited methicillin-resistant
S. aureus (MRSA), whilst being hemocompatible.
In an effort to protect Ti with a simple and convenient anti-
bacterial/antifouling coating, Guo et al. investigated coatings
of tannic acid (TA) and polyethylene glycols (PEGs);45 the Ti-
TA/PEG surface, formed from deposition (dip coating) from
a mixture of TA and PEG, rather than sequential dipping, pro-
duced a thicker coating that minimised bacterial adhesion,
prevented biofilm formation and reduced platelet adhesion.
Liu et al. capitalised on the strong covalent binding ability
of phosphonate groups to Ti to link cationic quaternary
ammonium polymers to Ti via metal-anchorable phospho-
nate motifs;46 excellent antibacterial properties were
reported.
Realising that most implant antimicrobial coatings are
fixed and predetermined prior to implantation, Czuban
et al. developed an alternative strategy:47 Ti was coated,
using a dip-coating procedure, with mussel-inspired dendritic
polyglycerol (MI-dPG) that could be locally activated with a
prodrug (daptomycin) to treat MRSA (Figure 4).
Dhingra et al. developed a polymer brush layer, via surface
initiated atom transfer radical polymerisation (SIATRP), onto
tartaric acid-based hydroxyl functionalised biodegradable ali-
phatic polyester (on glass), that displayed an optimal per-
formance of antimicrobial action and biocompatibility;48
there is a known trade-off between these properties.49 The
optimal polymer brush consisted of poly(2-[(methacryloylox-
y)ethyl] trimethyl ammonium chloride) (PMETA) brush and
was formed after 18 h (to establish a 400 nm optimum
brush length), exhibiting the highest antibacterial activity (>
97% and > 96% killing efficiency for E. coli and S. aureus,
respectively) and reasonable cytocompatibility (> 70%).
Figure 3. Strategies to prepare mechanically and chemically durable hydrophilic polymer-based coatings. Used with permission.42
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Wang et al. have developed a multifunctional (UV-absorb-
ing, self-healing, antibacterial, water-stable, glass-adhesive,
and abrasion-resistant) protective film for touch-screen
panels, utilising a novel nano-antimicrobial agent involving
polyquaternium-10 (PQ) and sodium alginate (SA) with TiO2
nanoparticles (PQ-TiO2-SA);
50 aSA-PQ microgel solution was
cast on to glass followed by cross-linking with peroxo
titanic acid and in situ formation of TiO2 nanoparticles
through hydrolysis of the peroxo titanic acid. Quercetin and
resveratrol nanoparticles were also incorporated to produce
a coating effective against S. aureus and E. coli.
Li et al. produced an antimicrobial graft polymer coating of
N-vinylpyrrolidone (NVP) and quaternary ammonium cations
of maleopimaric acid (GMA-MPA-N+), via surface-initiated
reversible addition–fragmentation chain-transfer polymeris-
ation, on polydimethylsiloxane (PDMS) silicone elastomer
(Figure 5);51 the coating showed biofilm inhibition to Gram
positive (S. aureus) and Gram negative (E. coli and
P. aeruginosa) bacteria for 21 days and significant platelet
adhesion, whilst maintaining biocompatibility. Low et al.
dip-coated silanised silicone (PDMS) in a solution of PCL,
PEG and antimicrobial peptide (AMP, an in-house synthetic
polypeptide), followed by a solution of ethyl cellulose (EC):
1-palmitoyl-2-oleoylphosphatidylcholine (POPC);52 the
coating was successful in targeting planktonic bacteria and
biofilm formation in urinary catheters. Sustained release
was achieved, and antibacterial (S. aureus, E. coli and
P. aeruginosa) activity was noted for over 6 days.
Hung et al. treated polypropylene with UV-ozone, to
expose carboxylic acid groups that were then converted to
anhydride groups to enable coupling of branched polyethyle-
neimine (PEI) containing various molecular mass styrene
maleic anhydride (SMA) crosslinkers;53 the coatings were
investigated in their inherent, cationic form, and as their
chlorinated derivatives. The best antimicrobial effect against
E. coli was with 6 kDa SMA and the coating was chlorinated
(and more stable).
Su et al. coated textile fabrics consisting of cotton, wool,
and polyethylene terephthalate with poly(catechol) and
poly(p-phenylenediamine) via in situ enzymatic polymeris-
ation of these monomers;54 antimicrobial activity against
S. aureus and E. coli was demonstrated.
Ahmadi and Ahmad developed an anti-corrosion and anti-
microbial polyurethane nanocomposite (PUC) containing
graphene oxide (GO), pongamia oil and acrylic acid (to
induce π-π interactions) that was applied to carbon steel
using a brush technique;55 GO additions of 0.5%wt increased
the anti-corrosion behaviour of the PUC (increased corrosion
potential and impedance modulus at low frequency;
decreased corrosion current density) even after 21 days and
was effective against S. aureus and E. coli.
Nguyen et al. reported that the topography of surfaces and
coatings can be tailored to reduce microbial attachment;56
self-organised wrinkles show particular promise (Figure 6).
Drug delivery
An historical perspective on the use of drug delivery systems
(e.g. nanoparticles, liposomes, hydrogels, cationic-and emul-
sion-based carriers) for use with osteoarthritis and rheuma-
toid arthritis patients has been presented by Saeedi et al.57
Advantages and disadvantages of the carrier systems are dis-
cussed, as are factors affecting delivery, such as charge, size,
structure and release rates. Jana et al. also provide a review of
drug delivery systems, some of which involve polymeric
coatings.58
β–Tricalcium phosphate (β–TCP) bioceramic is a resorb-
able bone graft, although drug delivery from this material is
too fast due to its microporosity.59 Khurana et al. used
plasma polymerisation (monomer: diethylene glycol dimethyl
ether) to produce PEG-like coatings (10–40 nm) on β–TCP
loaded with antibiotics (ampicillin and GS).59 The antimicro-
bial effect (S. aureus) was unaffected and the surfaces
remained cytocompatible (human osteosarcoma cells).
Yu et al. produced a drug-eluting polymer film by dip-
coating a silicone electrode array of a cochlear implant into
a precursor solution of poly lactic-co-glycolic acid (PLGA)
and trichloromethane containing one of three drugs (dexa-
methasone sodium phosphate, cytosine arabinoside hydro-
chloride or nicotinamide adenine dinucleotide).60 The drugs
were released in a sustained manner, showing promise for
reduced risk of intra-cochlear infection. Sevostyanov et al.
pulled metal stent wires through a solution of PLGA contain-
ing streptokinase, which is an enzyme with high thrombolytic
activity, followed by controlled evaporation steps.61 The
enzymes retained ca. 90% of their activity in the resultant
coating and were released in a controlled manner; no short-
term toxic effects on cells were shown by the polymer
coating.
Figure 4. Concept of inverse electron demand Diels-Alder reaction (IEDDA)-based titanium antimicrobial coating that concentrates, activates, and releases intra-
venously injected prodrug antimicrobial: (A) The tetrazine-coated prosthesis is implanted in the infected area, (B) caged prodrug added systemically, (C) prodrug
covalently reacts with the coated implant, and (D) IEDDA reaction uncages the prodrug, forming an active drug. Used with permission.47
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Figure 5. Preparation of dual-function antimicrobial coating using NVP and GMA-MPA-N+ via the reversible addition-fragmentation chain-transfer (RAFT) reaction.
Used with permission.51
Figure 6. Emerging antimicrobial wrinkled topographies can be categorised in four areas: chemically functionalised, graphene derivatised, metal incorporated,
and lubricant infused. Used with permission.56
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Al Subeh et al. coated fibrous meshes of polyglycolic acid
(PGA), formed by electrospinning, with poly(glycerol mono-
stearate co-ε-caprolactone) (PGC-C18) containing a novel
anticancer drug eupenifeldin, using a layer-by-layer tech-
nique;62 the coatings were introduced via a syringe and
time allowed for solvent (dichloromethane) evaporation
between layering. These buttresses were intended for use
as implants along the surgical margin following lung cancer
tumour resection. Prolonged drug release approaching 90
days was observed in vitro.
Response surface methodology (RSM) based on a central
composite design (CCD) was used by Moghimipour et al. to
evaluate the combination of pH and time-dependent
release of theophylline from gelatin capsules dip-coated in
hydroxypropyl methylcellulose (HPMC) and Eudragit® FS 30
D.63 Results indicated that the designed system could be
used as a carrier for colon drug delivery.
Barakh Ali et al. coated core tablets using an 8′′ Vector Hi-
Coater (with various inlet temperatures, bed temperatures,
pan rotation speeds, atomisation pressures and spray rates)
to 5 and 10% w/w mass gain with different polymer blends
to increase or prolong their dissolution and release of the
model drugs diclofenac sodium and prednisone;64 blends of
cellulose ester and enteric polymers were investigated.
A spray comprising the natural biopolymer pectin (a
bioadhesive hydrogel) and drug nanocrystals coated with
polylactic acid-polyethylene glycol (NCPPs) was proposed
for use in treatment of glioblastoma (malignant brain
tumour).65 The coating, stabilised with Pluronic F127, would
be sprayed on resected brain tissue; etoposide and olaparib
NCPPs at high drug loading showed in vitro stability and
drug release over 120 h.
Microneedle arrays (MNs) are a method of introducing
drugs across the skin overcoming the obvious disadvantages
of conventional hypodermic needles.66 A review on poly-
meric MNs has been published by Singh et al.67 Examples
of drugs used in MNs, include the influenza vaccine, lidocaine,
insulin, miconazole and 5-fluorouracil.68 Cárcamo-Martínez
et al. made MNs by pouring a Gantrez®S-97 (a copolymer of
methylvinylether and maleic acid (molecular mass
1,500 kDa) / PEG200 mixture) on a silicone mould.68 The
MNs were then coated (10 μL drop and left to dry) with a
model drug, 2 w/w% rhodamine B (in 20% PVP and 99.5%
ethanol, with different amounts of glycerol and Tween® 80),
to test their efficacy. Polymer MNs have the advantage of
improved biocompatibility, reduced fracture probability and
reduced likelihood of leaving fragments on the skin com-
pared with silicon, glass and ceramics MNs.
Xu et al. produced a curcumin polymer shell coating on
mesoporous silica nanoparticles (MSNs), using silane and
thiol coupling chemistry, for use in cancer treatment.69 The
polymer shell had three functions: (1) to gate MSN pores and
retained doxorubicin (DOX) within pores; (2) to degrade and
release curcumin (also an anticancer drug); and (3) aid fluor-
escence imaging as curcumin is self-fluorescent.
Deposition of CS on the surface of titanium nanotube
(TNT) arrays using a dip-coating process for the controlled
release of drugs was reported by Shidfar et al.; CS coating
thicknesses of 0, 0.29 and 0.45 μm achieved drug (gentami-
cin) release times for about 6, 8 and 12 days, respectively.70
Peng et al. coated Fe3O4 nanoparticles with zwitterionic
polymer membranes, via silane chemistry, to improve the
stability of the nanoparticles, which is important in drug
delivery for treating cancer, where long blood circulation is
required.71
Intrinsically conducting polymers (ICPs) use as drug deliv-
ery systems was recently reviewed by Puiggalí-Jou et al.72 The
review pays particular attention to drug release following
electrical stimuli, where charged drug molecules can be
expelled from the charged polymer matrix (Figure 7).
Electrochemical methods are also used to deposit ICPS
onto conducting substrates. Examples of drugs incorporated
in the review include: N-methylphenothiazine, phenothiazine,
quercetin, ciprofloxacin, neurotrophin-3, chlorpromazine,
brain-derived neurotrophic factor, risperidone, acetylcholine
chloride, dopamine hydrobromide, ibuprofen (anionic form),
methotrexate, heparin, ATP and betulin.
Although the use of conducting polymers and hydrogels
for drug release is not new, the combination of these
materials is an emerging area. Bansal et al. have reviewed
the use of conducting polymer hydrogels for such appli-
cations.73 Particular advantages include biocompatibility,
improved mechanical properties, increased drug loading
and ability to deliver hydrophilic drugs, although there are
only a few in vivo examples currently.
Tissue engineering
In an effort to mimic both the organic and inorganic phases of
bone extracellular matrix (ECM), Caddeo et al. utilised surface
silanisation with a successive chemical grafting technique to
coat slices of bioactive glass ceramic (representing the inor-
ganic phase of bone) with a type I collagen PU blend (repre-
senting the organic phase of bone).74 Results showed the
successful synthesis of a water soluble PU assessed as non-
toxic (MG-63 osteoblast-like cells), the collagen-PU coating
also demonstrated biocompatibility (human periosteal
derived precursor cells) with an increased deposition of
mineral matrix, suggesting the coated substrate has potential
for bone cell adhesion and growth.
Kiran et al. fabricated hybrid PCL/TiO2 coatings on com-
mercially pure Ti substrates, utilising electrospinning to fabri-
cate coatings with varying concentrations of TiO2
nanoparticles.75 The obtained nanocomposite scaffolds
exhibited bioactivity and improved biocompatibility when
compared with uncoated and PCL-coated substrates as well
Figure 7. Reversible redox activity of a conducting polymer between doped
(oxidised) and de-doped (reduced) states. Poly(3,4-ethylenedioxythiophene)
(PEDOT) is shown in the example.
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as antimicrobial activity (S. aureus), thought to be of use in
preventing potential infections.
Considering their ability to allow for autologous recellular-
isation, preservation of native vessel architecture and elimi-
nating cell-based antigens, decellularised vascular grafts
have recently been investigated within the field of tissue
engineering for their potential use in cardiac medicine.76,77
To reduce the risk of thrombosis and degeneration, Marinval
et al.76 and Iijima et al.77 have engineered coatings on decel-
lularised vascular grafts. To improve the re-endothelisation
and reduce the thrombogenicity and calcification of decellu-
larised porcine heart valves, Marinval et al.manually coated a
valve scaffold with 3 layers of a fucoidan / vascular endo-
thelial growth factor (VEGF) polyelectrolyte multilayer film
(PEM).76 The coating demonstrated the desired gain in antith-
rombotic activity without increasing calcification. The
modified scaffold also exhibited enhanced re-endothelisation
and improved potential for stem cells repopulation. Iijima
et al. coated the internal surfaces of aortic grafts (Wistar
rats) with a hydrogel-VEGF mixture by quickly warming to
37°C to polymerise the coating as a gel inside the lumen.77
In vivo results showed the coating stimulated medial recellu-
larisation and significantly increased endothelium formation
in comparison to the uncoated graft control group.
Cardiac remodelling is a common consequence of myocar-
dial infarction; recently, stem cell-based therapy has been
garnering attention as a potential approach to regenerate
cardiac tissue and prevent the formation of non-contractile
scar tissue. Chen et al. utilised electrospinning and layer-by-
layer coating technology to produce a cardiac patch-based
system utilising CS/silk fibroin, which was further engineered
to engraft adipose tissue-derived mesenchymal stem cells
(AD-MSCs).78 In vivo studies revealed the CS/silk fibroin
nanofibrous patches improved both viability and retention
of the engrafted AD-MSCs and demonstrated a reduction in
ventricular remodelling post MI.
To recreate the intrinsic hierarchy of tendons, Almeida
et al. developed a biomimetic scaffold using PCL, CS and cel-
lulose nanocrystals.79 The substrate’s surface stiffness was
reduced by coating with tropoelastin (TROPO) via PDA cross-
linking. In vitro testing with human adipose-derived stem cells
revealed that TROPO coatings sustained the tenogenic com-
mitment of stem cells, promoting faster cell elongation and
enabled the autologous synthesis of a tendon-like ECM.
Although PLLA is a promising biodegradable polymer within
cardiac research, it does have some disadvantages including
high hydrophobicity and reduced cell adhesion. Bolbasov
et al. modified the surface of PLLA with a thin titanium oxyni-
tride (TiOxNy) / titanium nitride (TiNx) / TiO / TiO2 mixed
coating utilising reactive magnetron sputtering within a nitro-
gen atmosphere.80 Various plasma treatment times were evalu-
ated to reveal that physico-mechanical properties of the scaffold
remained unchanged and hydrophobicity was decreased. No
adverse tissue reaction was documented during in vivo subcu-
taneous implantation (Wistar rats) of the modified PLLA
scaffolds up to 3 months and re-growth of replacement tissue
was discerned to depend upon plasma treatment time.
Lee et al. developed a ‘nature-inspired catechol-conju-
gated hyaluronic acid environment’ coating platform
(NiCHE) for enhancing the efficacy of salivary gland tissue.81
The NiCHE coating (adhesive hyaluronic acid−catechol),
dip-coated onto PCL scaffolds and polycarbonate, increased
proliferation of vascular endothelial cells.
Although PLGA, PGA and PLA are widely utilised within the
field of tissue engineering there are some disadvantages to
their use, including inflammatory responses linked to the
release of acidic products during degradation. To address
this issue, Shen et al. detail the production of unidirectional
shell–core structured fibres of CS/poly(lactide-co-glycolide)
via coaxial electrospinning.82 CS has an acid-neutralising
capability, and the coatings established on the PLGA fibres
slowed the pH decrease associated with degradation of
PLGA in vitro as well as significantly reducing the production
of inflammatory factors and down-regulating (reducing) the
expression of related inflammatory genes (human dermal
fibroblasts). Further biocompatibility assays showed the
coated fibres to be biocompatible, in vivo testing (subcu-
taneous implantation) demonstrated that the CS coating
decreased the recruitment of inflammatory cells and the for-
mation of foreign body giant cells.
Landry et al. reveal the challenges associated with long-
term primary neural cell culture including the juxtaposition
of providing a surface that is not only soft and hydrophilic
but also robust and bound strongly enough to the underlying
surface to provide an adequate support for long-term cell
growth.83 To this end, the authors also reviewed recent devel-
opments of new artificial extracellular matrix (ECM) surfaces
for in vitro neural cell culture.
Shrestha et al. utilised electrospinning to produce a self-
electrical stimulated double-layered nerve guidance conduit
creating a bioactive framework of CS-grafted PU integrated
with functionalised multiwall carbon nanotubes and coated
with PPy.84 The structural framework exhibited biocompat-
ibility; aligned orientated fibres showed accelerated
regrowth, proliferation and migration of Schwann cells and
differentiation of rat pheochromocytoma cells compared to
randomly orientated mats exemplifying the potential of
nerve guidance conduits for use in nerve tissue regeneration.
To address the issue of chronically implanted microelec-
trode array (MEA) isolation from the brain due to foreign
body response, Cassar et al. developed an electrodeposited
platinum–iridium coating for use with penetrating recording
MEAs.85 In vivo testing led to the conclusion that coated MEAs
provided improved recording performance in comparison to
uncoated arrays.
Yan et al. coated a silk fibroin sponge internally and exter-
nally with collagen (dip-coating followed by a crosslinking
step) that was used to replace the meniscus (stabilising carti-
lage) of the knee removed during menisectomy (removal of
this cartilage).86 The scaffold produced demonstrated that
the collagen coating improved biocompatibility, frictional
properties and tissue ingrowth of the sponge in vivo.
Recognising the need for bioactive composite scaffolds
with favourable mechanical properties, Luo et al. utilised
3D-printing and in-situ mineralisation to produce alginate/
gelatin scaffolds with a homogenous nano apatite coating;
the coating thickness could be controlled by the phosphate
ion concentration.87 In comparison to uncoated scaffolds,
the coated scaffold exhibited superior mechanical properties
(2-fold higher Young’s modulus), and accelerated prolifer-
ation and osteogenic differentiation of rat bone marrow cells.
Biosensors
Methods used for depositing nanomaterials onto electrode
surfaces to produce efficient biosensors have been reviewed
by Ahmad et al.88 These are grouped broadly into coatings,
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direct deposition, printing and direct growth, which are
further subdivided. Protein-resistant polymer coating strat-
egies for biosensors and biomaterials have been reviewed
and discussed by Zhang et al.89 A review by Chen and Noy
categorises the antifouling strategies to protect bioelectronic
devices;90 relevant to polymer coatings, self-polishing, temp-
erature-responsive, pH-responsive, phospholipid coatings
(that mimic cell membranes), PEGs, polymer brushes, and
hydrogel coatings are described. Xu and Lee have also
reviewed various strategies used to prolong the life of biosen-
sors, particularly in the area of delaying biofouling through
the use of various hydrophilic, biomimetic, drug-eluting, zwit-
terionic, and other smart polymer materials.91 PEGs and zwit-
terionic polymers are considered ‘gold standards’ as coatings
for reducing biofouling of biosensors, although Chan et al.
reported success in using a polyacrylamide-based copolymer
hydrogel for this application;92 certain copolymer compo-
sitions showed better performance than the gold standards.
Burugapalli et al. used electrospun membranes of PU and
gelatin to produce in vivo implantable glucose biosensors of
high sensitivity.93
Liu et al. reported a PVP coating that protects MNs (vertical
ZnO nanowires) for use in transdermal biosensing of H2O2;
94
PVP was spray-coated on to MN surface and offered a 3-fold
protection over uncoated surfaces.
The entrapment of Aspergillusniger (a fungus) in ICPs, such
as PPy, is an established method of producing amperometric
glucose sensors.95 Apetrei et al. found that the sensitivity of
such biosensors was improved by forming PPy in situ with
the cellular membrane/wall.95
Conclusions
Polymer coatings are invaluable in the field of biomedical
applications, due to their biocompatibility, functionality,
durability and stability (chemical, biological and physical).
Thus, these coatings find applications in orthopaedics, cardi-
ovascular stents, antibacterial surfaces, drug delivery, tissue
engineering and biosensors, among other lesser studied
applications. Ceramic coatings are also of great interest,
although the applications currently tend to be more
focused in the area of orthopaedic implants.
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